PDF(Pubmed)
Abstract：
The use of cancer immunotherapies is not novel but has been used over the decades in the clinic. Only recently have we found the true potential of stimulating an anti-tumor response after the breakthrough of checkpoint inhibitors. Cancer immunotherapies have become the first line treatment for many malignancies at various stages. Nevertheless, the clinical results in terms of overall survival and progression free survival were not as anticipated. Majority of cancer patients do not respond to immunotherapies and the reasons differ. Hence, further improvements for cancer immunotherapies are crucially needed. In the review, we will discuss various forms of cancer immunotherapies that are being tested or already in the clinic. Moreover, we also highlight future directions to improve such therapies.
摘要：
癌症免疫疗法的使用并不新颖，但已在临床上使用了数十年。直到最近，我们才发现在检查点抑制剂突破后刺激抗肿瘤反应的真正潜力。癌症免疫疗法已成为许多不同阶段恶性肿瘤的一线治疗方法。然而，总生存期和无进展生存期方面的临床结果不如预期.大多数癌症患者对免疫疗法没有反应，原因不同。因此，迫切需要进一步改进癌症免疫疗法.在审查中,我们将讨论正在测试或已经在临床中的各种形式的癌症免疫疗法。此外，我们还强调了改进此类疗法的未来方向。
